Reviva Pharmaceuticals Holdings (RVPH) Price & Analysis

Compare

1,039 Followers

RVPH Stock Chart & Stats

$0.28

-$0.09(-4.50%)

At close: Jan 08 4:00 PM EST

$0.28

-$0.09(-4.50%)

Day’s Range― - ―

52-Week Range$0.25 - $2.95

Previous CloseN/A

Volume1.63M

Average Volume (3M)14.40M

Market Cap

$31.99M

Enterprise Value$13.61M

Total Cash (Recent Filing)$13.18M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Mar 23, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding115,058,620

10 Day Avg. Volume22,198,486

30 Day Avg. Volume14,401,288

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)73.84

Price to Sales (P/S)0.00

P/FCF Ratio-1.79

Enterprise Value/Market Cap0.43

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.60

Forecast

1Y Price Target

$5.10

Price Target Upside1721.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyTreatment with brilaroxazine demonstrated broad-spectrum efficacy sustained over 1-year, including improvements in symptoms such as PANSS total score, positive and negative symptoms, and personal & social performance.

Financial StrengtheningReviva announced an equity financing of $9M in gross proceeds raised through the issuance of shares of common stock, with additional funds raised from warrant exercises, extending their financial runway.

Regulatory AdvancesThe upcoming pre-NDA meeting with the FDA will clarify the regulatory path for brilaroxazine in schizophrenia and determine whether an additional P3 study will be required. A favorable outcome could position Reviva for an NDA submission based on positive P2, P3 (RECOVER-1), 1-year open label extension study, and pharmacology study data.

Bears Say

Completion RisksRisks include inability to complete pivotal development of brilaroxazine in schizophrenia in a timely manner.

Development DelaysIn written feedback, the FDA recommended a second Phase 3 clinical trial for brilaroxazine in patients with schizophrenia to generate additional efficacy data and expand the safety dataset.

Regulatory ChallengesRegulatory feedback mandates a confirmatory registrational trial.

Reviva Pharmaceuticals Holdings News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Infosys (INFY) 47.38% +29.74,...

3d ago

NNE

WWR

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/24/25

The Vanguard Total Stock Market ETF ($VTI), which provides broad exposure to the entire U.S. stock market, is...

3d ago

VTI

Reviva Pharmaceuticals price target lowered to $1.50 from $3 at Roth Capital

Roth Capital lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $1.50 from $3 and keeps a...

3d ago

RVPH

H.C. Wainwright still sees schizophrenia approval for Reviva in 2028

H.C. Wainwright analyst Raghuram Selvaraju reiterates a Buy rating on Reviva Pharmaceuticals (RVPH) with a $4 price target...

3d ago

RVPH

Roth says Reviva may need additional $60M-$75M for schizophrenia study

After Reviva Pharmaceuticals (RVPH) announced that the FDA recommended a second Phase 3 clinical trial for brilaroxazine in...

4d ago

RVPH

Reviva Pharmaceuticals announces regulatory update regarding brilaroxazine

Reviva Pharmaceuticals (RVPH) announced a regulatory update following a pre-New Drug Application meeting with the U.S. Food and...

4d ago

RVPH

Reviva Pharmaceuticals discloses feedback from FDA on brilaroxazine

In a regulatory filing, the company stated: “On December 23, 2025, the Company issued a press release providing...

4d ago

RVPH

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Nano Nuclear Energy Inc...

10d ago

BTQ

EFA

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: PharmaCyte Biotech (PMCB) 279.47%...

12d ago

NNE

STM

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: db X trackers China...

17d ago

BRR

ASHR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: iRobot (IRBT) 122.08% +7.18,...

19d ago

TMQ

BITU

Reviva Pharmaceuticals: Buy Rating Reaffirmed as Additional Phase 3 Trial Leaves Schizophrenia Launch and DCF‑Backed Upside Intact

Reviva Pharmaceuticals Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

3d ago

RVPH

Reviva plans second Phase 3 trial after FDA feedback

Reviva Pharmaceuticals Holdings ( ($RVPH) ) has shared an announcement. At its annual meeting on December 18, 2025,...

4d ago

RVPH

Reviva Pharmaceuticals: Promising Future with Strong Financial Position and Positive Regulatory Outlook

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Reviva Pharmaceuticals Holdings, retaining the price target...

1M ago

RVPH

RVPH FAQ

What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?

Reviva Pharmaceuticals Holdings lowest stock price was $0.25 and its highest was $2.95 in the past 12 months.

What is Reviva Pharmaceuticals Holdings’s market cap?

Reviva Pharmaceuticals Holdings’s market cap is $31.99M.

When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?

Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Mar 23, 2026 which is in 86 days.

How were Reviva Pharmaceuticals Holdings’s earnings last quarter?

Reviva Pharmaceuticals Holdings released its earnings results on Nov 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.095 by $0.035.

Is Reviva Pharmaceuticals Holdings overvalued?

According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Reviva Pharmaceuticals Holdings pay dividends?

Reviva Pharmaceuticals Holdings does not currently pay dividends.

What is Reviva Pharmaceuticals Holdings’s EPS estimate?

Reviva Pharmaceuticals Holdings’s EPS estimate is -0.06.

How many shares outstanding does Reviva Pharmaceuticals Holdings have?

Reviva Pharmaceuticals Holdings has 115,058,620 shares outstanding.

What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?

Reviva Pharmaceuticals Holdings reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.095. Following the earnings report the stock price went down -7.407%.

Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?

Currently, no hedge funds are holding shares in RVPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Reviva Pharmaceuticals Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

44.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Reviva Pharmaceuticals Holdings (RVPH) Earnings & Revenues

Historic Earnings Reports

RVPH Stock 12 Month Forecast

Average Price Target

$5.10

▲(1721.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","-1":"-$1","3.5":"$3.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.5,8,12.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.62,1.8030769230769232,2.9861538461538464,4.1692307692307695,5.352307692307693,6.535384615384616,7.718461538461539,8.901538461538461,10.084615384615384,11.267692307692307,12.45076923076923,13.633846153846154,14.816923076923077,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.62,0.9646153846153847,1.3092307692307692,1.6538461538461537,1.9984615384615383,2.343076923076923,2.687692307692308,3.0323076923076924,3.376923076923077,3.7215384615384615,4.066153846153846,4.4107692307692306,4.7553846153846155,{"y":5.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.62,0.6876923076923077,0.7553846153846153,0.823076923076923,0.8907692307692308,0.9584615384615385,1.0261538461538462,1.0938461538461537,1.1615384615384614,1.2292307692307691,1.2969230769230768,1.3646153846153846,1.4323076923076923,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >